NewHavenBIZ

n e w h a v e n b i z . c o m | J u n e 2 0 2 2 | n e w h a v e n B I Z 21 P O W E R 2 5 : H e a l t h c a r e 2 0 2 2 past November, and he says his background as a doctor will help him as he works to build the organiza- tion, increase ser- vices and improve patient care. Lundbye is a cardiologist and internal medicine physician, and also teaches at the University of Connecticut, where he is an associate professor of medicine. Lundbye now leads the entire health network, which includes Waterbury Hos- pital, Alliance Medical Group, Cardiolo- gy Associates of Greater Waterbury, VNA Health at Home, Access Rehab Centers, and the Greater Waterbury Imaging Center. e network provides primary, emer- gency and home health care to Water- bury and several surrounding commu- nities. Lundbye had most recently served as senior vice president and chief medical officer of Waterbury Hospital, a role he had since December 2016. During the pandemic, Lundbye has led testing and vaccination efforts, and served as the network's primary medical spokesman. Lundbye said his goals include provid- ing high-quality care at an appropriate value. He also aims to retain and attract employees, and ensure the system's work- ers are happy and have pride in what they do. ere has been a widespread nurs- ing shortage, and Lundbye has put an emphasis on continuing to recruit nurses. e health system has expanded in the area of cardiac care, and plans to continue to do so, according to Lundbye, so patients don't have to travel to get the care and novel therapies they need. Lundbye also has been supportive of a proposed partnership with Yale New Haven Health, which in February announced it had signed an agreement with Prospect Medical Holdings Inc. to acquire some of its holdings, including Waterbury HEALTH. e deal is under regulatory review. If finalized, the Water- bury network would return to nonprofit status. Dr. Brigette Roberts, CEO, AI Therapeutics Dr. Brigette Roberts is leading AI erapeutics Inc., a Guilford-based clini- cal-stage biopharmaceutical company, as its chief executive officer. Roberts took over officially in Febru- ary, aer serving in the role as act- ing chief executive since May 2021. Roberts has more than two decades of experi- ence in healthcare investment and biotechnology entrepreneurship. According to the company, Roberts has already fortified its founding mission of bringing life-saving drugs to patients with rare diseases, including by rais- ing more than $28 million in private investment capital to advance its product pipeline. Under her leadership, the company initiated a Phase 2 clinical trial for a ther- apy to treat patients with amyotrophic lateral sclerosis, and set the groundwork for multiple Phase 2 studies for condi- tions such as pulmonary sarcoidosis, bronchiolitis obliterans syndrome and pulmonary arterial hypertension. In April, the company announced it had acquired a new cancer drug can- didate from Spain's EntreChem S.L., as a potential treatment for rare pediatric and other cancers. Roberts previously served as an entre- preneur in residence at Fortress Biotech. Roberts has said AI erapeutics has a "tremendous opportunity" to help ad- vance drug treatments for underserved patients suffering from rare diseases, and she notes there are more than 7,000 known rare diseases that impact more than 25 million Americans. In addition to being a doctor, Rob- erts has a background as an investor and entrepreneur, with a track record of building biotechnology companies. She spent more than 15 years in health- care investing as a portfolio manager at hedge funds including ird Point, CDP Capital, Angel Lane Principal Strategies, DKR Capital and her own hedge fund, YYC Capital. Dr. Keith Churchwell, President, Yale New Haven Hospital As a longtime cardiologist and leader of the Greater New Haven region's largest hospital, Dr. Keith Churchwell is known for putting his heart into his profession. Churchwell, who took over as presi- dent at Yale New Haven Hospital in October 2020, is focused on running the non- profit hospital, which has 1,541 beds and attracts patients from around the country and world. Yale New Haven Hospital also includes Smilow Cancer Hospital at Yale New Haven, Yale New Haven Children's Hospital and Yale New Haven Psychiatric Hospital. Churchwell, the hospital's first Black president, first came to work there in 2015, and he is board certified in inter- nal medicine and cardiovascular disease. He was promoted to president aer first serving as the hospital's chief operating officer and executive vice president. Churchwell is on the board of direc- tors for the American Heart Association, and he has been a national advocate for change. He has called for enhanced access to quality, affordable care to improve health outcomes for mothers. Churchwell has also called attention to structural racism and its impact on health, including on cardiovascular disease. e coronavirus pandemic has been at the forefront throughout Churchwell's tenure as the hospital's president. He has been focused on making sure patients get the best care, while also supporting staff and ensuring safety. Churchwell is also an associate clinical professor of medicine (cardiology) at Yale School of Medicine. e Nashville, Tennessee native has been active on area boards, including for the New Haven Symphony, Columbus House and New England Donor Services. His commu- nity outreach has included going out to meet people with his "Walk with a Doc" sessions in the Dixwell and Newhallville neighborhoods of New Haven. Dr. Manisha Juthani, Commissioner, Department of Public Health Dr. Manisha Juthani serves as com- missioner of the Connecticut Depart- ment of Public Health, responsible for helping to im- prove the health and safety of the state's residents. Gov. Ned Lamont named her acting com- missioner in July 2021, and she officially assumed the role this spring. Juthani is an infectious diseases physician at the Yale School of Medicine, and she has specialized in the diagnosis, management, and prevention of infec- tions in older adults. She arrived at Yale in 2002 for in- fectious diseases fellowship training, then later joined the faculty full time in 2006. She assumed the role of infectious diseases fellowship program director in 2012. In nominating Juthani, Lamont said her background in infectious diseases would benefit state residents as poli- cymakers continue responding to the COVID-19 pandemic and implementing policies to help keep transmission rates low. Following her nomination, Juthani said she would focus not only on COVID-19, but continuing the state's efforts related to mental health, health equity, health disparities, and access to health care. Juthani's federally-funded research has primarily focused on infections in older adults, such as urinary tract infections and pneumonia. She was a principal investigator in a study that concluded cranberry capsules had no impact on urinary tract infections in women in nursing homes. Her research has garnered widespread attention in the media, including in outlets such as the New York Times and CNN. Juthani has frequently spoken and written about medical topics in the press. During the COVID-19 pandemic, she has had a leadership role in the response at Yale. She has helped educate the pub- lic about the disease, via media outlets ranging from the Wall Street Journal and USA Today to the Washington Post. Dr. Brian Holzer, CEO, and Dr. Andrea Auxier, President, Aware Recovery Care e two new top leaders at Aware Recovery Care, a Wallingford-based addiction-treat- ment business, hope to change the lives of those battling substance abuse. Dr. Brian Holzer joined Aware as its new chief executive officer in April, while Dr. Andrea Auxier was promoted to president in February. Aware Recovery Care provides team- based, in-home addiction treatment in Connecticut, Maine, New Hampshire, Massachusetts, Rhode Island, Virginia, Florida, Ohio and Indiana. Both will lead the company as it con- tinues its planned expansion to additional markets around the country. Holzer's background includes more than two decades in strategy, operations, marketing and sales in large and small public and private healthcare companies. Before joining Aware Recovery Care, his most recent role had been as president of innovations at Kindred Healthcare, and he has also worked at Highmark Health and its hospital system, Allegheny Health Network. Auxier, before being promoted to president, had previously served as the company's chief growth officer. Prior to joining Aware Recovery Care, she was the chief commercial officer for New Direc- tions Behavioral Health and served as the national director of integration at Beacon Health Options. As president of Aware Recovery Care, Auxier will lead the execution of the com- pany's vision, strategies and goals. Vimal Mehta, Co-Founder & CEO, BioXcel Therapeutics Vimal Mehta is chief executive officer and a co-founder of BioXcel erapeutics, a New Hav- en-based company making strides developing treat- ments for cancer and agitation in people suffering from Alzheimer's disease, schizo- phrenia and bipolar disorder. Mehta has more than two decades of experience in the pharmaceutical and biotech industries, including prior roles at Inpharmatica Ltd., Jubilant Life Sciences and CuraGen Corp. BioXcel uses artificial intelligence to develop medicines in the areas of neuro- science and immuno-oncology. Under Mehta's leadership, the company has been making headlines in recent months for advancements in its pipeline. In May, the company announced it had dosed its first patient in a Phase 3 study of its drug candidate for agitation in patients with Alzheimer's disease. e study is evaluating the safety and effectiveness of BXCL501, an orally-dissolving thin film formulation of dexmedetomidine. e U.S. Food and Drug Adminis- tration recently approved the use of BXCL501 for the acute treatment of agitation in adults with schizophrenia and bipolar disorder. e drug, called IGAL- MI, is the company's first FDA-approved Continued on next page

• Cover